recently, new psychoactive substances (NPS) have swiftly emerged during the drug marketplace for a “lawful” choice to controlled drugs1, two. The expression “NPS” involves distinctive compound households, such as synthetic cannabinoids, cathinones and opioids. In the final 10 years, an increase in using synthetic opioids as compound of abus